

Key:	>>> ... marks correct (expected) result	N ... number of the results
	> ... marks conditionally correct (acceptable) result	Nrel ... relative number of the results
	± ... marks the result not evaluated	

Test

Sample	Group	N	Result	N _{rel}
--------	-------	---	--------	------------------

Set 1 and 2

(700) AB0 blood group

E1 and S1 (6) APR	>>>	3	Blood group: A	1,9 %
(14) Bio-Rad	>>>	52	Blood group: A	33 %
(40) Ortho Clinical Diagnostics	>>>	2	Blood group: A	1,3 %
(52) Dynex	>>>	2	Blood group: A	1,3 %
(64) Exbio Olomouc	>>>	11	Blood group: A	6,9 %
(80) DiaMed	>>>	17	Blood group: A	11 %
(159) Grifols	>>>	31	Blood group: A	19 %
(172) Immucor	>>>	20	Blood group: A	13 %
(173) Sanguin	>>>	8	Blood group: A	5,0 %
(174) IVT Imuno	>>>	8	Blood group: A	5,0 %
(203) ANTITOXIN	>>>	2	Blood group: A	1,3 %
(999) another manufacturer	>>>	4	Blood group: A	2,5 %
Total per sample: n = 160		Success: 100 %		

E2 and S2 (6) APR	>>>	3	Blood group: 0	1,9 %
(14) Bio-Rad	>>>	52	Blood group: 0	33 %
(40) Ortho Clinical Diagnostics	>>>	2	Blood group: 0	1,3 %
(52) Dynex	>>>	2	Blood group: 0	1,3 %
(64) Exbio Olomouc	>>>	11	Blood group: 0	6,9 %
(80) DiaMed	>>>	17	Blood group: 0	11 %
(159) Grifols	>>>	31	Blood group: 0	19 %
(172) Immucor	>>>	20	Blood group: 0	13 %
(173) Sanguin	>>>	8	Blood group: 0	5,0 %
(174) IVT Imuno	>>>	8	Blood group: 0	5,0 %
(203) ANTITOXIN	>>>	2	Blood group: 0	1,3 %
(999) another manufacturer	>>>	4	Blood group: 0	2,5 %
Total per sample: n = 160		Success: 100 %		

Total success: 100 %

(703) A subgroup

E1 and S1 (0) not specified	>>>	54	A subgroup A1	100 %
Total per sample: n = 54		Success: 100 %		

E2 and S2 (0) not specified	>>>	54	Not specified	100 %
Total per sample: n = 54		Success: 100 %		

Total success: 100 %

(705) Rh D antigen (blood-donor)

E1 and S1 (0) not specified	>>>	1	Negative (RhD-)	1,1 %
(6) APR	>>>	2	Negative (RhD-)	2,2 %
(14) Bio-Rad	>>>	27	Negative (RhD-)	29 %
(40) Ortho Clinical Diagnostics	>>>	1	Negative (RhD-)	1,1 %
(52) Dynex	>>>	2	Negative (RhD-)	2,2 %
(64) Exbio Olomouc	>>>	5	Negative (RhD-)	5,4 %
(80) DiaMed	>>>	7	Negative (RhD-)	7,5 %
(159) Grifols	>>>	15	Negative (RhD-)	16 %
(172) Immucor	>>>	21	Negative (RhD-)	23 %
(173) Sanguin	>>>	4	Negative (RhD-)	4,3 %
(174) IVT Imuno	>>>	4	Negative (RhD-)	4,3 %
(203) ANTITOXIN	>>>	2	Negative (RhD-)	2,2 %
(999) another manufacturer	>>>	2	Negative (RhD-)	2,2 %
Total per sample: n = 93		Success: 100 %		

E2 and S2 (0) not specified	>>>	1	Positive (RhD+)	1,1 %
(6) APR	>>>	2	Positive (RhD+)	2,2 %
(14) Bio-Rad	>>>	27	Positive (RhD+)	29 %
(40) Ortho Clinical Diagnostics	>>>	1	Positive (RhD+)	1,1 %
(52) Dynex	>>>	2	Positive (RhD+)	2,2 %
(64) Exbio Olomouc	>>>	5	Positive (RhD+)	5,4 %
(80) DiaMed	>>>	7	Positive (RhD+)	7,5 %
(159) Grifols	>>>	15	Positive (RhD+)	16 %
(172) Immucor	>>>	21	Positive (RhD+)	23 %
(173) Sanguin	>>>	4	Positive (RhD+)	4,3 %
(174) IVT Imuno	>>>	4	Positive (RhD+)	4,3 %
(203) ANTITOXIN	>>>	2	Positive (RhD+)	2,2 %
(999) another manufacturer	>>>	2	Positive (RhD+)	2,2 %
Total per sample: n = 93		Success: 100 %		

Test

Sample	Group	N	Result	N _{rel}
Total success: 100 %				
(709) Rh D antigen (recipient)				
E1 and S1 (6) APR		>>> 3	Negative (RhD-)	2,0 %
(14) Bio-Rad		>>> 45	Negative (RhD-)	30 %
(40) Ortho Clinical Diagnostics		>>> 2	Negative (RhD-)	1,4 %
(50) Merck		>>> 1	Negative (RhD-)	0,68 %
(52) Dynex		>>> 2	Negative (RhD-)	1,4 %
(64) Exbio Olomouc		>>> 8	Negative (RhD-)	5,4 %
(80) DiaMed		>>> 14	Negative (RhD-)	9,5 %
(159) Grifols		>>> 32	Negative (RhD-)	22 %
(172) Immucor		>>> 22	Negative (RhD-)	15 %
(173) Sanguin		>>> 5	Negative (RhD-)	3,4 %
(174) IVT Imuno		>>> 7	Negative (RhD-)	4,7 %
(203) ANTITOXIN		>>> 2	Negative (RhD-)	1,4 %
(999) another manufacturer		>>> 5	Negative (RhD-)	3,4 %
Total per sample: n = 148		Success: 100 %	-	
E2 and S2 (6) APR		>>> 3	Positive (RhD+)	2,0 %
(14) Bio-Rad		>>> 45	Positive (RhD+)	30 %
(40) Ortho Clinical Diagnostics		>>> 2	Positive (RhD+)	1,4 %
(50) Merck		>>> 1	Positive (RhD+)	0,68 %
(52) Dynex		>>> 2	Positive (RhD+)	1,4 %
(64) Exbio Olomouc		>>> 8	Positive (RhD+)	5,4 %
(80) DiaMed		>>> 14	Positive (RhD+)	9,5 %
(159) Grifols		>>> 32	Positive (RhD+)	22 %
(172) Immucor		>>> 22	Positive (RhD+)	15 %
(173) Sanguin		>>> 5	Positive (RhD+)	3,4 %
(174) IVT Imuno		>>> 7	Positive (RhD+)	4,7 %
(203) ANTITOXIN		>>> 2	Positive (RhD+)	1,4 %
(999) another manufacturer		>>> 5	Positive (RhD+)	3,4 %
Total per sample: n = 148		Success: 100 %	-	
Total success: 100 %				

(715) Antigen C

E1 and S1 (6) APR		>>> 1	Negative	1,3 %
(14) Bio-Rad		>>> 31	Negative	41 %
(64) Exbio Olomouc		>>> 1	Negative	1,3 %
(80) DiaMed		>>> 6	Negative	8,0 %
(159) Grifols		>>> 15	Negative	20 %
(172) Immucor		>>> 12	Negative	16 %
(173) Sanguin		>>> 2	Negative	2,7 %
(174) IVT Imuno		>>> 3	Negative	4,0 %
(203) ANTITOXIN		>>> 3	Negative	4,0 %
(999) another manufacturer		>>> 1	Negative	1,3 %
Total per sample: n = 75		Success: 100 %	-	
E2 and S2 (6) APR		>>> 1	Positive	1,3 %
(14) Bio-Rad		>>> 31	Positive	41 %
(64) Exbio Olomouc		>>> 1	Positive	1,3 %
(80) DiaMed		>>> 6	Positive	8,0 %
(159) Grifols		>>> 15	Positive	20 %
(172) Immucor		>>> 12	Positive	16 %
(173) Sanguin		>>> 2	Positive	2,7 %
(174) IVT Imuno		>>> 3	Positive	4,0 %
(203) ANTITOXIN		>>> 3	Positive	4,0 %
(999) another manufacturer		>>> 1	Positive	1,3 %
Total per sample: n = 75		Success: 100 %	-	
Total success: 100 %				

(716) Antigen c

E1 and S1 (6) APR		>>> 1	Positive	1,3 %
(14) Bio-Rad		>>> 31	Positive	41 %
(64) Exbio Olomouc		>>> 1	Positive	1,3 %
(80) DiaMed		>>> 6	Positive	8,0 %
(159) Grifols		>>> 15	Positive	20 %
(172) Immucor		>>> 12	Positive	16 %
(173) Sanguin		>>> 2	Positive	2,7 %
(174) IVT Imuno		>>> 3	Positive	4,0 %
(203) ANTITOXIN		>>> 3	Positive	4,0 %
(999) another manufacturer		>>> 1	Positive	1,3 %
Total per sample: n = 75		Success: 100 %	-	
E2 and S2 (6) APR		>>> 1	Negative	1,3 %

EQA round: IH4/21 - Blood Group Serology

Deadline: 19.11.2021

Test

Sample	Group	N	Result	N _{rel}
E2 and S2 (14)	Bio-Rad	>>>	31 Negative	41 %
	(64) Exbio Olomouc	>>>	1 Negative	1,3 %
	(80) DiaMed	>>>	6 Negative	8,0 %
	(159) Grifols	>>>	15 Negative	20 %
	(172) Immucor	>>>	12 Negative	16 %
	(173) Sanguin	>>>	2 Negative	2,7 %
	(174) IVT Imuno	>>>	3 Negative	4,0 %
	(203) ANTITOXIN	>>>	3 Negative	4,0 %
	(999) another manufacturer	>>>	1 Negative	1,3 %
Total per sample: n = 75			Success: 100 %	
Total success: 100 %				

(717) Antigen Cw

E1 and S1 (6)	APR	>>>	1 Negative	1,6 %
	(14) Bio-Rad	>>>	22 Negative	36 %
	(52) Dynex	>>>	1 Negative	1,6 %
	(64) Exbio Olomouc	>>>	1 Negative	1,6 %
	(80) DiaMed	>>>	2 Negative	3,3 %
	(159) Grifols	>>>	14 Negative	23 %
	(172) Immucor	>>>	12 Negative	20 %
	(173) Sanguin	>>>	4 Negative	6,6 %
	(174) IVT Imuno	>>>	2 Negative	3,3 %
	(203) ANTITOXIN	>>>	2 Negative	3,3 %
Total per sample: n = 61			Success: 100 %	
E2 and S2 (6)	APR	>>>	1 Negative	1,6 %
	(14) Bio-Rad	>>>	22 Negative	36 %
	(52) Dynex	>>>	1 Negative	1,6 %
	(64) Exbio Olomouc	>>>	1 Negative	1,6 %
	(80) DiaMed	>>>	2 Negative	3,3 %
	(159) Grifols	>>>	14 Negative	23 %
	(172) Immucor	>>>	12 Negative	20 %
	(173) Sanguin	>>>	4 Negative	6,6 %
	(174) IVT Imuno	>>>	2 Negative	3,3 %
	(203) ANTITOXIN	>>>	2 Negative	3,3 %
Total per sample: n = 61			Success: 100 %	
Total success: 100 %				

(718) Antigen E

E1 and S1 (6)	APR	>>>	1 Negative	1,3 %
	(14) Bio-Rad	>>>	31 Negative	41 %
	(64) Exbio Olomouc	>>>	1 Negative	1,3 %
	(80) DiaMed	>>>	6 Negative	8,0 %
	(159) Grifols	>>>	15 Negative	20 %
	(172) Immucor	>>>	12 Negative	16 %
	(173) Sanguin	>>>	2 Negative	2,7 %
	(174) IVT Imuno	>>>	3 Negative	4,0 %
	(203) ANTITOXIN	>>>	3 Negative	4,0 %
	(999) another manufacturer	>>>	1 Negative	1,3 %
Total per sample: n = 75			Success: 100 %	
E2 and S2 (6)	APR	>>>	1 Negative	1,3 %
	(14) Bio-Rad	>>>	31 Negative	41 %
	(64) Exbio Olomouc	>>>	1 Negative	1,3 %
	(80) DiaMed	>>>	6 Negative	8,0 %
	(159) Grifols	>>>	15 Negative	20 %
	(172) Immucor	>>>	12 Negative	16 %
	(173) Sanguin	>>>	2 Negative	2,7 %
	(174) IVT Imuno	>>>	3 Negative	4,0 %
	(203) ANTITOXIN	>>>	3 Negative	4,0 %
	(999) another manufacturer	>>>	1 Negative	1,3 %
Total per sample: n = 75			Success: 100 %	
Total success: 100 %				

(719) Antigen e

E1 and S1 (6)	APR	>>>	1 Positive	1,3 %
	(14) Bio-Rad	>>>	31 Positive	41 %
	(64) Exbio Olomouc	>>>	1 Positive	1,3 %
	(80) DiaMed	>>>	6 Positive	8,0 %
	(159) Grifols	>>>	15 Positive	20 %
	(172) Immucor	>>>	12 Positive	16 %
	(173) Sanguin	>>>	2 Positive	2,7 %

EQA round: IH4/21 - Blood Group Serology

Deadline: 19.11.2021

Test		N	Result	N _{rel}	
Sample	Group				
E1 and S1 (174) IVT Imuno	>>>	3	Positive	4,0 %	
	(203) ANTITOXIN	>>>	3	Positive	4,0 %
	(999) another manufacturer	>>>	1	Positive	1,3 %
	Total per sample: n = 75		Success: 100 %		
E2 and S2 (6) APR	>>>	1	Positive	1,3 %	
	(14) Bio-Rad	>>>	31	Positive	41 %
	(64) Exbio Olomouc	>>>	1	Positive	1,3 %
	(80) DiaMed	>>>	6	Positive	8,0 %
	(159) Grifols	>>>	15	Positive	20 %
	(172) Immucor	>>>	12	Positive	16 %
	(173) Sanguin	>>>	2	Positive	2,7 %
	(174) IVT Imuno	>>>	3	Positive	4,0 %
	(203) ANTITOXIN	>>>	3	Positive	4,0 %
	(999) another manufacturer	>>>	1	Positive	1,3 %
	Total per sample: n = 75		Success: 100 %		
Total success: 100 %					
(720) Antigen K					
E1 and S1 (6) APR	>>>	1	Negative	1,3 %	
	(14) Bio-Rad	>>>	28	Negative	36 %
	(80) DiaMed	>>>	6	Negative	7,7 %
	(159) Grifols	>>>	19	Negative	24 %
	(172) Immucor	>>>	12	Negative	15 %
	(173) Sanguin	>>>	3	Negative	3,8 %
	(174) IVT Imuno	>>>	5	Negative	6,4 %
	(203) ANTITOXIN	>>>	2	Negative	2,6 %
	(999) another manufacturer	>>>	2	Negative	2,6 %
	Total per sample: n = 78		Success: 100 %		
E2 and S2 (6) APR	>>>	1	Negative	1,3 %	
	(14) Bio-Rad	>>>	28	Negative	36 %
	(80) DiaMed	>>>	6	Negative	7,7 %
	(159) Grifols	>>>	19	Negative	24 %
	(172) Immucor	>>>	12	Negative	15 %
	(173) Sanguin	>>>	3	Negative	3,8 %
	(174) IVT Imuno	>>>	5	Negative	6,4 %
	(203) ANTITOXIN	>>>	2	Negative	2,6 %
	(999) another manufacturer	>>>	2	Negative	2,6 %
	Total per sample: n = 78		Success: 100 %		
Total success: 100 %					
(721) Antigen k					
E1 and S1 (0) not specified	>>>	2	Positive	4,5 %	
	(6) APR	>>>	1	Positive	2,3 %
	(14) Bio-Rad	>>>	10	Positive	23 %
	(64) Exbio Olomouc	>>>	6	Positive	14 %
	(80) DiaMed	>>>	2	Positive	4,5 %
	(159) Grifols	>>>	6	Positive	14 %
	(172) Immucor	>>>	5	Positive	11 %
	(173) Sanguin	>>>	7	Positive	16 %
	(174) IVT Imuno	>>>	1	Positive	2,3 %
	(203) ANTITOXIN	>>>	3	Positive	6,8 %
	(999) another manufacturer	>>>	1	Positive	2,3 %
	Total per sample: n = 44		Success: 100 %		
	E2 and S2 (0) not specified	>>>	2	Positive	4,5 %
(6) APR		>>>	1	Positive	2,3 %
(14) Bio-Rad		>>>	10	Positive	23 %
(64) Exbio Olomouc		>>>	6	Positive	14 %
(80) DiaMed		>>>	2	Positive	4,5 %
(159) Grifols		>>>	6	Positive	14 %
(172) Immucor		>>>	5	Positive	11 %
(173) Sanguin		>>>	7	Positive	16 %
(174) IVT Imuno		>>>	1	Positive	2,3 %
(203) ANTITOXIN		>>>	3	Positive	6,8 %
(999) another manufacturer		>>>	1	Positive	2,3 %
Total per sample: n = 44		Success: 100 %			
Total success: 100 %					
(722) Antigen M					
E1 and S1 (6) APR	>>>	1	Positive	2,6 %	
	(14) Bio-Rad	>>>	9	Positive	23 %

EQA round: IH4/21 - Blood Group Serology

Deadline: 19.11.2021

Test		N	Result	N _{rel}
Sample	Group			
E1 and S1	(52) Dynex	>>> 1	Positive	2,6 %
	(64) Exbio Olomouc	>>> 4	Positive	10 %
	(80) DiaMed	>>> 1	Positive	2,6 %
	(159) Grifols	>>> 4	Positive	10 %
	(172) Immucor	>>> 14	Positive	36 %
	(173) Sanguin	>>> 2	Positive	5,1 %
	(183) Immunodiagnostic Systems	>>> 1	Positive	2,6 %
	(203) ANTITOXIN	>>> 2	Positive	5,1 %
Total per sample: n = 39		Success: 100 %	-	-
E2 and S2	(6) APR	>>> 1	Positive	2,6 %
	(14) Bio-Rad	>>> 9	Positive	23 %
	(52) Dynex	>>> 1	Positive	2,6 %
	(64) Exbio Olomouc	>>> 4	Positive	10 %
	(80) DiaMed	>>> 1	Positive	2,6 %
	(159) Grifols	>>> 4	Positive	10 %
	(172) Immucor	>>> 14	Positive	36 %
	(173) Sanguin	>>> 2	Positive	5,1 %
	(183) Immunodiagnostic Systems	>>> 1	Positive	2,6 %
	(203) ANTITOXIN	>>> 2	Positive	5,1 %
Total per sample: n = 39		Success: 100 %	-	-

Total success: 100 %

(723) Antigen N

E1 and S1	(6) APR	>>> 1	Positive	2,9 %
	(14) Bio-Rad	>>> 9	Positive	26 %
	(52) Dynex	>>> 2	Positive	5,7 %
	(64) Exbio Olomouc	>>> 2	Positive	5,7 %
	(80) DiaMed	>>> 1	Positive	2,9 %
	(159) Grifols	>>> 4	Positive	11 %
	(172) Immucor	>>> 11	Positive	31 %
	(173) Sanguin	>>> 2	Positive	5,7 %
	(183) Immunodiagnostic Systems	>>> 1	Positive	2,9 %
	(203) ANTITOXIN	>>> 2	Positive	5,7 %
Total per sample: n = 35		Success: 100 %	-	-
E2 and S2	(6) APR	>>> 1	Positive	2,9 %
	(14) Bio-Rad	>>> 9	Positive	26 %
	(52) Dynex	>>> 2	Positive	5,7 %
	(64) Exbio Olomouc	>>> 2	Positive	5,7 %
	(80) DiaMed	>>> 1	Positive	2,9 %
	(159) Grifols	>>> 4	Positive	11 %
	(172) Immucor	>>> 11	Positive	31 %
	(173) Sanguin	>>> 2	Positive	5,7 %
	(183) Immunodiagnostic Systems	>>> 1	Positive	2,9 %
	(203) ANTITOXIN	>>> 2	Positive	5,7 %
Total per sample: n = 35		Success: 100 %	-	-

Total success: 100 %

(724) Antigen S

E1 and S1	(6) APR	>>> 1	Negative	2,6 %
	(14) Bio-Rad	>>> 9	Negative	23 %
	(50) Merck	>>> 1	Negative	2,6 %
	(52) Dynex	>>> 2	Negative	5,1 %
	(64) Exbio Olomouc	>>> 2	Negative	5,1 %
	(80) DiaMed	>>> 1	Positive	2,6 %
	(80) DiaMed	>>> 2	Negative	5,1 %
	(159) Grifols	>>> 6	Negative	15 %
	(172) Immucor	>>> 7	Negative	18 %
	(173) Sanguin	>>> 4	Negative	10 %
	(174) IVT Imuno	>>> 2	Negative	5,1 %
	(203) ANTITOXIN	>>> 2	Negative	5,1 %
Total per sample: n = 39		Success: 97 %	-	-
E2 and S2	(6) APR	>>> 1	Negative	2,6 %
	(14) Bio-Rad	>>> 9	Negative	23 %
	(50) Merck	>>> 1	Negative	2,6 %
	(52) Dynex	>>> 2	Negative	5,1 %
	(64) Exbio Olomouc	>>> 3	Negative	7,7 %
	(80) DiaMed	>>> 2	Negative	5,1 %
	(159) Grifols	>>> 6	Negative	15 %
	(172) Immucor	>>> 7	Negative	18 %
	(173) Sanguin	>>> 4	Negative	10 %

EQA round: IH4/21 - Blood Group Serology

Deadline: 19.11.2021

Test

Sample	Group	N	Result	N _{rel}
E2 and S2 (174)	IVT Imuno	>>>	2 Negative	5,1 %
(203)	ANTITOXIN	>>>	2 Negative	5,1 %
Total per sample: n = 39		Success: 100 %		
Total success: 97 %				

(725) Antigen s

E1 and S1 (6)	APR	>>>	1 Positive	2,6 %
(14)	Bio-Rad	>>>	9 Positive	23 %
(52)	Dynex	>>>	1 Positive	2,6 %
(64)	Exbio Olomouc	>>>	4 Positive	10 %
(80)	DiaMed	>>>	2 Positive	5,1 %
(159)	Grifols	>>>	6 Positive	15 %
(172)	Immucor	>>>	7 Positive	18 %
(173)	Sanguin	>>>	5 Positive	13 %
(174)	IVT Imuno	>>>	2 Positive	5,1 %
(203)	ANTITOXIN	>>>	2 Positive	5,1 %
Total per sample: n = 39		Success: 100 %		
E2 and S2 (6)	APR	>>>	1 Positive	2,6 %
(14)	Bio-Rad	>>>	9 Positive	23 %
(52)	Dynex	>>>	1 Positive	2,6 %
(64)	Exbio Olomouc	>>>	4 Positive	10 %
(80)	DiaMed	>>>	2 Positive	5,1 %
(159)	Grifols	>>>	6 Positive	15 %
(172)	Immucor	>>>	7 Positive	18 %
(173)	Sanguin	>>>	5 Positive	13 %
(174)	IVT Imuno	>>>	2 Positive	5,1 %
(203)	ANTITOXIN	>>>	2 Positive	5,1 %
Total per sample: n = 39		Success: 100 %		
Total success: 100 %				

(726) Antigen P1

E1 and S1 (6)	APR	>>>	1 Positive	3,4 %
(14)	Bio-Rad	>>>	7 Positive	24 %
(64)	Exbio Olomouc	>>>	3 Positive	10 %
(80)	DiaMed	>>>	1 Positive	3,4 %
(159)	Grifols	>>>	1 Positive	3,4 %
(172)	Immucor	>>>	9 Positive	31 %
(173)	Sanguin	>>>	5 Positive	17 %
(174)	IVT Imuno	>>>	1 Positive	3,4 %
(203)	ANTITOXIN	>>>	1 Positive	3,4 %
Total per sample: n = 29		Success: 100 %		
E2 and S2 (6)	APR	>>>	1 Positive	3,4 %
(14)	Bio-Rad	>>>	7 Positive	24 %
(64)	Exbio Olomouc	>>>	3 Positive	10 %
(80)	DiaMed	>>>	1 Positive	3,4 %
(159)	Grifols	>>>	1 Positive	3,4 %
(172)	Immucor	>>>	9 Positive	31 %
(173)	Sanguin	>>>	5 Positive	17 %
(174)	IVT Imuno	>>>	1 Positive	3,4 %
(203)	ANTITOXIN	>>>	1 Positive	3,4 %
Total per sample: n = 29		Success: 100 %		
Total success: 100 %				

(727) Antigen Fya

E1 and S1 (14)	Bio-Rad	>>>	11 Negative	28 %
(64)	Exbio Olomouc	>>>	4 Negative	10 %
(80)	DiaMed	>>>	2 Negative	5,0 %
(159)	Grifols	>>>	6 Negative	15 %
(172)	Immucor	>>>	8 Negative	20 %
(173)	Sanguin	>>>	5 Negative	13 %
(174)	IVT Imuno	>>>	2 Negative	5,0 %
(203)	ANTITOXIN	>>>	2 Negative	5,0 %
Total per sample: n = 40		Success: 100 %		
E2 and S2 (14)	Bio-Rad	>>>	11 Positive	28 %
(64)	Exbio Olomouc	>>>	1 Negative	2,5 %
		>>>	3 Positive	7,5 %
(80)	DiaMed	>>>	2 Positive	5,0 %
(159)	Grifols	>>>	6 Positive	15 %
(172)	Immucor	>>>	8 Positive	20 %
(173)	Sanguin	>>>	5 Positive	13 %

EQA round: IH4/21 - Blood Group Serology

Deadline: 19.11.2021

Test

Sample	Group	N	Result	N _{rel}
E2 and S2 (174)	IVT Imuno	>>> 2	Positive	5,0 %
(203)	ANTITOXIN	>>> 2	Positive	5,0 %
Total per sample: n = 40		Success: 98 %		
Total success: 98 %				

(728) Antigen Fyb

E1 and S1 (14)	Bio-Rad	>>> 11	Positive	28 %
(64)	Exbio Olomouc	>>> 4	Positive	10 %
(80)	DiaMed	>>> 2	Positive	5,0 %
(159)	Grifols	>>> 6	Positive	15 %
(172)	Immucor	>>> 8	Positive	20 %
(173)	Sanguin	>>> 5	Positive	13 %
(174)	IVT Imuno	>>> 2	Positive	5,0 %
(203)	ANTITOXIN	>>> 2	Positive	5,0 %
Total per sample: n = 40		Success: 100 %		
E2 and S2 (14)	Bio-Rad	>>> 11	Positive	28 %
(64)	Exbio Olomouc	>>> 4	Positive	10 %
(80)	DiaMed	>>> 2	Positive	5,0 %
(159)	Grifols	>>> 6	Positive	15 %
(172)	Immucor	>>> 8	Positive	20 %
(173)	Sanguin	>>> 5	Positive	13 %
(174)	IVT Imuno	>>> 2	Positive	5,0 %
(203)	ANTITOXIN	>>> 2	Positive	5,0 %
Total per sample: n = 40		Success: 100 %		
Total success: 100 %				

(729) Antigen Jka

E1 and S1 (6)	APR	>>> 1	Negative	2,4 %
(14)	Bio-Rad	>>> 11	Negative	27 %
(50)	Merck	>>> 1	Negative	2,4 %
(52)	Dynex	>>> 3	Negative	7,3 %
(64)	Exbio Olomouc	>>> 1	Negative	2,4 %
			1	2,4 %
(80)	DiaMed	>>> 2	Negative	4,9 %
(159)	Grifols	>>> 7	Negative	17 %
(172)	Immucor	>>> 7	Negative	17 %
(173)	Sanguin	>>> 5	Negative	12 %
(203)	ANTITOXIN	>>> 2	Negative	4,9 %
Total per sample: n = 41		Success: 98 %		
E2 and S2 (6)	APR	>>> 1	Positive	2,4 %
(14)	Bio-Rad	>>> 11	Positive	27 %
(50)	Merck	>>> 1	Positive	2,4 %
(52)	Dynex	>>> 3	Positive	7,3 %
(64)	Exbio Olomouc	>>> 2	Positive	4,9 %
(80)	DiaMed	>>> 2	Positive	4,9 %
(159)	Grifols	>>> 7	Positive	17 %
(172)	Immucor	>>> 7	Positive	17 %
(173)	Sanguin	>>> 5	Positive	12 %
(203)	ANTITOXIN	>>> 2	Positive	4,9 %
Total per sample: n = 41		Success: 100 %		
Total success: 98 %				

(730) Antigen Jkb

E1 and S1 (6)	APR	>>> 1	Positive	2,4 %
(14)	Bio-Rad	>>> 11	Positive	27 %
(50)	Merck	>>> 1	Positive	2,4 %
(52)	Dynex	>>> 3	Positive	7,3 %
(64)	Exbio Olomouc	>>> 2	Positive	4,9 %
(80)	DiaMed	>>> 2	Positive	4,9 %
(159)	Grifols	>>> 7	Positive	17 %
(172)	Immucor	>>> 7	Positive	17 %
(173)	Sanguin	>>> 5	Positive	12 %
(203)	ANTITOXIN	>>> 2	Positive	4,9 %
Total per sample: n = 41		Success: 100 %		
E2 and S2 (6)	APR	>>> 1	Negative	2,4 %
(14)	Bio-Rad	>>> 11	Negative	27 %
(50)	Merck	>>> 1	Negative	2,4 %
(52)	Dynex	>>> 3	Negative	7,3 %
(64)	Exbio Olomouc	>>> 1	Negative	2,4 %
			1	2,4 %

EQA round: IH4/21 - Blood Group Serology

Deadline: 19.11.2021

Test			N	Result	N _{rel}
Sample	Group				
E2 and S2	(80) DiaMed	>>>	2	Negative	4,9 %
	(159) Grifols	>>>	7	Negative	17 %
	(172) Immucor	>>>	7	Negative	17 %
	(173) Sanguin	>>>	5	Negative	12 %
	(203) ANTITOXIN	>>>	2	Negative	4,9 %
Total per sample: n = 41		Success: 98 %			
Total success: 98 %					
(731) Antigen Lua					
E1 and S1	(14) Bio-Rad	>>>	10	Negative	38 %
	(64) Exbio Olomouc	>>>	2	Negative	7,7 %
	(80) DiaMed	>>>	2	Negative	7,7 %
	(159) Grifols	>>>	6	Negative	23 %
	(172) Immucor	>>>	4	Negative	15 %
	(173) Sanguin	>>>	1	Negative	3,8 %
	(203) ANTITOXIN	>>>	1	Negative	3,8 %
Total per sample: n = 26		Success: 100 %			
E2 and S2	(14) Bio-Rad	>>>	10	Negative	38 %
	(64) Exbio Olomouc	>>>	2	Negative	7,7 %
	(80) DiaMed	>>>	2	Negative	7,7 %
	(159) Grifols	>>>	6	Negative	23 %
	(172) Immucor	>>>	4	Negative	15 %
	(173) Sanguin	>>>	1	Negative	3,8 %
	(203) ANTITOXIN	>>>	1	Negative	3,8 %
Total per sample: n = 26		Success: 100 %			
Total success: 100 %					
(732) Antigen Lub					
E1 and S1	(14) Bio-Rad	>>>	8	Positive	31 %
	(64) Exbio Olomouc	>>>	2	Positive	7,7 %
	(80) DiaMed	>>>	2	Positive	7,7 %
	(159) Grifols	>>>	5	Positive	19 %
	(172) Immucor	>>>	4	Positive	15 %
	(173) Sanguin	>>>	1	Positive	3,8 %
	(203) ANTITOXIN	>>>	2	Positive	7,7 %
	(999) another manufacturer	>>>	2	Positive	7,7 %
Total per sample: n = 26		Success: 100 %			
E2 and S2	(14) Bio-Rad	>>>	8	Positive	31 %
	(64) Exbio Olomouc	>>>	2	Positive	7,7 %
	(80) DiaMed	>>>	2	Positive	7,7 %
	(159) Grifols	>>>	5	Positive	19 %
	(172) Immucor	>>>	4	Positive	15 %
	(173) Sanguin	>>>	1	Positive	3,8 %
	(203) ANTITOXIN	>>>	2	Positive	7,7 %
	(999) another manufacturer	>>>	2	Positive	7,7 %
Total per sample: n = 26		Success: 100 %			
Total success: 100 %					
(733) Antigen Lea					
E1 and S1	(14) Bio-Rad	>>>	8	Negative	24 %
	(50) Merck	>>>	1	Negative	3,0 %
	(52) Dynex	>>>	2	Negative	6,1 %
	(64) Exbio Olomouc	>>>	1	Negative	3,0 %
	(80) DiaMed	>>>	2	Negative	6,1 %
	(159) Grifols	>>>	3	Negative	9,1 %
	(172) Immucor	>>>	10	Negative	30 %
	(173) Sanguin	>>>	2	Negative	6,1 %
	(174) IVT Imuno	>>>	2	Negative	6,1 %
	(203) ANTITOXIN	>>>	2	Negative	6,1 %
Total per sample: n = 33		Success: 100 %			
E2 and S2	(14) Bio-Rad	>>>	8	Negative	24 %
	(50) Merck	>>>	1	Negative	3,0 %
	(52) Dynex	>>>	2	Negative	6,1 %
	(64) Exbio Olomouc	>>>	1	Negative	3,0 %
	(80) DiaMed	>>>	2	Negative	6,1 %
	(159) Grifols	>>>	3	Negative	9,1 %
	(172) Immucor	>>>	10	Negative	30 %
	(173) Sanguin	>>>	2	Negative	6,1 %
	(174) IVT Imuno	>>>	2	Negative	6,1 %
	(203) ANTITOXIN	>>>	2	Negative	6,1 %

Test

Sample	Group	N	Result	N _{rel}
Total per sample: n = 33		Success: 100 %		
Total success: 100 %				

(734) Antigen Leb

E1 and S1	(14) Bio-Rad	>>>	8	Positive	24 %
	(50) Merck	>>>	1	Positive	3,0 %
	(52) Dynex	>>>	2	Positive	6,1 %
	(64) Exbio Olomouc	>>>	1	Positive	3,0 %
	(80) DiaMed	>>>	1	Positive	3,0 %
	(159) Grifols	>>>	1	Negative	3,0 %
		>>>	3	Positive	9,1 %
	(172) Immucor	>>>	10	Positive	30 %
	(173) Sanguin	>>>	2	Positive	6,1 %
	(174) IVT Imuno	>>>	2	Positive	6,1 %
	(203) ANTITOXIN	>>>	2	Positive	6,1 %
Total per sample: n = 33		Success: 97 %			
E2 and S2	(14) Bio-Rad	>>>	8	Positive	24 %
	(50) Merck	>>>	1	Positive	3,0 %
	(52) Dynex	>>>	2	Positive	6,1 %
	(64) Exbio Olomouc	>>>	1	Positive	3,0 %
	(80) DiaMed	>>>	1	Positive	3,0 %
	(159) Grifols	>>>	4	Positive	12 %
	(172) Immucor	>>>	10	Positive	30 %
	(173) Sanguin	>>>	2	Positive	6,1 %
	(174) IVT Imuno	>>>	2	Positive	6,1 %
	(203) ANTITOXIN	>>>	2	Positive	6,1 %
Total per sample: n = 33		Success: 100 %			
Total success: 97 %					

(737) Direct Coombs (antiglobulin) test

E1 and S1	(6) APR	>>>	1	Negative	0,77 %
	(14) Bio-Rad	>>>	59	Negative	45 %
	(40) Ortho Clinical Diagnostics	>>>	2	Negative	1,5 %
	(64) Exbio Olomouc	>>>	2	Negative	1,5 %
	(80) DiaMed	>>>	25	Negative	19 %
	(159) Grifols	>>>	38	Negative	29 %
	(173) Sanguin	>>>	1	Negative	0,77 %
	(174) IVT Imuno	>>>	1	Negative	0,77 %
	(203) ANTITOXIN	>>>	1	Negative	0,77 %
Total per sample: n = 130		Success: 100 %			
E2 and S2	(6) APR	>>>	1	Negative	0,77 %
	(14) Bio-Rad	>>>	59	Negative	45 %
	(40) Ortho Clinical Diagnostics	>>>	2	Negative	1,5 %
	(64) Exbio Olomouc	>>>	2	Negative	1,5 %
	(80) DiaMed	>>>	25	Negative	19 %
	(159) Grifols	>>>	38	Negative	29 %
	(173) Sanguin	>>>	1	Negative	0,77 %
	(174) IVT Imuno	>>>	1	Negative	0,77 %
	(203) ANTITOXIN	>>>	1	Negative	0,77 %
Total per sample: n = 130		Success: 100 %			
Total success: 100 %					

(741) Antibody screening (IAT, blood donor)

E1 and S1	(0) not specified	>>>	2	Positive	2,4 %
	(6) APR	>>>	4	Positive	4,9 %
	(14) Bio-Rad	>>>	31	Positive	38 %
	(40) Ortho Clinical Diagnostics	>>>	1	Positive	1,2 %
	(64) Exbio Olomouc	>>>	1	Positive	1,2 %
	(80) DiaMed	>>>	14	Positive	17 %
	(159) Grifols	>>>	18	Positive	22 %
	(172) Immucor	>>>	11	Positive	13 %
Total per sample: n = 82		Success: 100 %			
E2 and S2	(0) not specified	>>>	2	Positive	2,4 %
	(6) APR	>>>	4	Positive	4,9 %
	(14) Bio-Rad	>	27	Negative	33 %
		>>>	4	Positive	4,9 %
	(40) Ortho Clinical Diagnostics	>>>	1	Positive	1,2 %
	(64) Exbio Olomouc	>	1	Negative	1,2 %
	(80) DiaMed	>	13	Negative	16 %
		>>>	1	Positive	1,2 %
	(159) Grifols	>	3	Negative	3,7 %

EQA round: IH4/21 - Blood Group Serology

Deadline: 19.11.2021

Test

Sample	Group	N	Result	N _{rel}
E2 and S2 (159)	Grifols	>>> 15	Positive	18 %
(172)	Immucor	> 3	Negative	3,7 %
		>>> 8	Positive	9,8 %
Total per sample: n = 82		Success: 100 %		
Total success: 100 %				

(743) Antibody screening (IAT, recipient)

E1 and S1 (0)	not specified	>>> 1	Positive	0,72 %
(6)	APR	>>> 3	Positive	2,2 %
(14)	Bio-Rad	>>> 66	Positive	47 %
(40)	Ortho Clinical Diagnostics	>>> 2	Positive	1,4 %
(80)	DiaMed	>>> 27	Positive	19 %
(159)	Grifols	>>> 36	Positive	26 %
(172)	Immucor	>>> 4	Positive	2,9 %
Total per sample: n = 139		Success: 100 %		
E2 and S2 (0)	not specified	> 1	Negative	0,72 %
(6)	APR	>>> 3	Positive	2,2 %
(14)	Bio-Rad	> 56	Negative	40 %
		>>> 10	Positive	7,2 %
(40)	Ortho Clinical Diagnostics	>>> 2	Positive	1,4 %
(80)	DiaMed	> 25	Negative	18 %
		>>> 2	Positive	1,4 %
(159)	Grifols	> 4	Negative	2,9 %
		>>> 32	Positive	23 %
(172)	Immucor	>>> 4	Positive	2,9 %
Total per sample: n = 139		Success: 100 %		
Total success: 100 %				

(745) Antibody screening (IAT, pregnant)

E1 and S1 (6)	APR	>>> 3	Positive	2,6 %
(14)	Bio-Rad	>>> 53	Positive	46 %
(40)	Ortho Clinical Diagnostics	>>> 2	Positive	1,7 %
(64)	Exbio Olomouc	>>> 1	Positive	0,86 %
(80)	DiaMed	>>> 20	Positive	17 %
(159)	Grifols	>>> 33	Positive	28 %
(172)	Immucor	>>> 4	Positive	3,4 %
Total per sample: n = 116		Success: 100 %		
E2 and S2 (6)	APR	>>> 3	Positive	2,6 %
(14)	Bio-Rad	> 43	Negative	37 %
		>>> 10	Positive	8,6 %
(40)	Ortho Clinical Diagnostics	>>> 2	Positive	1,7 %
(64)	Exbio Olomouc	> 1	Negative	0,86 %
(80)	DiaMed	> 19	Negative	16 %
		>>> 1	Positive	0,86 %
(159)	Grifols	> 4	Negative	3,4 %
		>>> 29	Positive	25 %
(172)	Immucor	>>> 4	Positive	3,4 %
Total per sample: n = 116		Success: 100 %		
Total success: 100 %				

(747) Antibody screening (enzyme test)

E1 and S1 (14)	Bio-Rad	15	Negative	15 %
		>>> 37	Positive	36 %
(40)	Ortho Clinical Diagnostics	1	Negative	0,97 %
		>>> 1	Positive	0,97 %
(80)	DiaMed	2	Negative	1,9 %
		>>> 18	Positive	17 %
(159)	Grifols	>>> 28	Positive	27 %
(172)	Immucor	>>> 1	Positive	0,97 %
Total per sample: n = 103		Success: 83 %		
E2 and S2 (14)	Bio-Rad	1	Negative	0,97 %
		>>> 51	Positive	50 %
(40)	Ortho Clinical Diagnostics	>>> 2	Positive	1,9 %
(80)	DiaMed	1	Negative	0,97 %
		>>> 19	Positive	18 %
(159)	Grifols	>>> 28	Positive	27 %
(172)	Immucor	>>> 1	Positive	0,97 %
Total per sample: n = 103		Success: 98 %		
Total success: 82 %				

(750) Antibody identification

Summary statistics - qualitative results

(Groups: manufacturer of kit)

EQA round: IH4/21 - Blood Group Serology

Deadline: 19.11.2021

Test		N	Result	N _{rel}
Sample	Group			
E1 and S1 (0) not specified		3	anti-K	6,7 %
		>>> 42	anti-K; anti-Kpa	93 %
Total per sample: n = 45		Success: 93 %		
E2 and S2 (0) not specified		>	Not specified	2,2 %
		>	Antibody not present	2,2 %
		>>> 43	anti-Jkb	96 %
Total per sample: n = 45		Success: 100 %		
Total success: 93 %				
(752) Antibody titre, Sample 1: 1st antibody				
E1 and S1 (0) not specified		± 12	titre 16	39 %
		± 18	titre 32	58 %
		± 1	titre 128	3,2 %
Total per sample: n = 31		Success (only evaluated results):	evaluation	
(753) Antibody titre, Sample 1: 2nd antibody				
E1 and S1 (0) not specified		± 2	titre 0 (not measurable)	7,4 %
		± 8	titre 1	30 %
		± 14	titre 2	52 %
		± 3	titre 4	11 %
Total per sample: n = 27		Success (only evaluated results):	evaluation	
(756) Antibody titre, Sample 2: 1st antibody				
E2 and S2 (0) not specified		± 4	titre 0 (not measurable)	19 %
		± 10	titre 1	48 %
		± 3	titre 2	14 %
		± 3	titre 4	14 %
		± 1	titre 64	4,8 %
Total per sample: n = 21		Success (only evaluated results):	evaluation	
Set 3				
(760) Crossmatch				
S1	All results	1	Crossmatch not successful	0,80 %
		>>> 124	Crossmatch successful	99 %
Total per sample: n = 125		Success: 99 %		
S2	All results	>>> 125	Crossmatch successful	100 %
Total per sample: n = 125		Success: 100 %		
Total success: 99 %				
(761) Crossmatch (segment K1)				
S1	(0) not specified	>>> 124	Negative test	99 %
		1	Positive test	0,80 %
Total per sample: n = 125		Success: 99 %		
S2	(0) not specified	>	Negative test	78 %
		>>> 28	Positive test	22 %
Total per sample: n = 125		Success: 100 %		
Total success: 99 %				
(762) Serve transfusion product (segment K1)				
S1	(0) not specified	± 3	Impossible, risk of haemolysis	2,4 %
		± 72	Decision depends on results of other tests not performed in our laboratory	58 %
		± 19	Only if more suitable products are not available	15 %
		± 31	Possible	25 %
Total per sample: n = 125		Success (only evaluated results):	evaluation	
S2	(0) not specified	± 46	Impossible, risk of haemolysis	37 %
		± 45	Decision depends on results of other tests not performed in our laboratory	36 %
		± 8	Only if more suitable products are not available	6,4 %
		± 26	Possible	21 %
Total per sample: n = 125		Success (only evaluated results):	evaluation	
(764) Crossmatch (segment K2)				
S1	(0) not specified	1	Negative test	0,80 %
		>>> 124	Positive test	99 %
Total per sample: n = 125		Success: 99 %		
S2	(0) not specified	>>> 125	Negative test	100 %
Total per sample: n = 125		Success: 100 %		
Total success: 99 %				
(765) Serve transfusion product (segment K2)				
S1	(0) not specified	± 121	Impossible, risk of haemolysis	97 %
		± 2	Decision depends on results of other tests not	1,6 %

Summary statistics - qualitative results

(Groups: manufacturer of kit)

EQA round: IH4/21 - Blood Group Serology

Deadline: 19.11.2021

Test

Sample	Group	N	Result	N _{rel}
S1			performed in our laboratory	
		± 1	Only if more suitable products are not available	0,80 %
		± 1	Possible	0,80 %
----- Total per sample: n = 125 ----- Success (only evaluated results): evaluation-----				
S2	(0) not specified	± 3	Impossible, risk of haemolysis	2,4 %
		± 51	Decision depends on results of other tests not performed in our laboratory	41 %
		± 21	Only if more suitable products are not available	17 %
		± 50	Possible	40 %
----- Total per sample: n = 125 ----- Success (only evaluated results): evaluation-----				

st_kl End of report

Printed: 04.12.2021